[chart]investorshub.advfn.com/uimage/uploads/2017/6/28/lmzwbrabits.jpg[/chart]
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ALKM Missing the point of my post!
The U.S. Securities and Exchange Commission has moved a key step closer to eliminating an auditing requirement for smaller companies as part of its effort to incentivize businesses to use the public capital markets.
At its meeting on Thursday, the SEC voted 3-1 to advance a proposed rule that would exempt smaller reporting companies (SRCs) from outside audits of their internal controls for preventing accounting errors and fraud.
Under the Sarbanes-Oxley financial reforms of 2002, such ICFR audits are required for public companies categorized as either accelerated or large accelerated filers. As a result of amendments adopted last year, some companies were classified as both SRCs and accelerated or large accelerated filers, making them subject to ICFR audits.
The amendments approved on Thursday exclude from the accelerated and large accelerated filer definitions “an issuer that is eligible to be an SRC and had no revenues or annual revenues of less than $100 million in the most recent fiscal year for which audited financial statements are available.”
“The proposed rules build on the JOBS Act of 2012 and are aimed at a subset of smaller companies where the additional requirement of an ICFR auditor attestation may not be an efficient way of benefiting and protecting investors,” SEC Chairman Jay Clayton said in a news release.
“Investors in these lower-revenue companies will benefit from more tailored control requirements,” he added, suggesting that many of them, including those in the biotech and health care sectors, “will be able to redirect the savings into growing their companies by investing in research and human capital.”
As The Wall Street Journal reports, “Republicans in Congress and industry groups such as the U.S. Chamber of Commerce have long advocated repealing or easing the auditing requirements, arguing that expensive audits would deter businesses from becoming public companies.”
The proposed SEC rule will now be subject to a 60-day public comment period.
https://www.cfo.com/banking-capital-markets/2019/05/sec-approves-audit-exemption-for-smaller-firms/
Creative Medical Technology Holdings Partners with Edge Media Network to Accelerate CaverStem(R) Adoption
7:45 AM ET 9/11/19 | Dow Jones
Fully integrated campaign expected to drive 6M+ impressions and over 20,000 entries in promotion to provide a complimentary CaverStem(R) procedure performed by Dr. Scott Sanderson, MD at one of the newest CaverStem(R) Centers of Excellence: Elite Health Hawaii
PHOENIX, Sept. 11, 2019 /PRNewswire/ -- Creative Medical Technology Holdings (OTC-CELZ) reported today it has signed an agreement with Edge Media Network to introduce CaverStem(R) to their community in an integrated campaign spanning web, email, social media, and in-person events.
"We are excited to work with Creative Medical Technology Holdings to introduce CaverStem(R) to our 5 million readers and provide lucky winners the opportunity to receive this life-changing procedure," said EDGE Media Network founder and publisher David Foucher. "As the world's leading LGBTQ news and entertainment platform, we are always on the lookout for innovation that has the potential to improve the lives of our community, and CMTH's science-based approach to treating erectile dysfunction without drugs certainly fits the bill."
The contest which is slated to run October 1, 2019-December 20, 2019 is sure to bring holiday cheer to the winners of the robust giveaways:
-- Grand Prize: 4 nights, 5 days all-inclusive trip to Honolulu, Hawaii and
a CaverStem(R) procedure performed by Dr. Scott Sanderson at Elite Health
Hawaii.
-- Runner-Up: Free CaverStem(R) procedure at a Center of Excellence of their
choosing and $1,000 to cover travel related expenses
-- Additional Prizes: Three additional winners will get 50% off procedure
cards.
"On the heels of our announcement last week regarding completion of our clinical trial for CaverStem(R), we are thrilled to partner with Edge Media Network to share this breakthrough treatment with their readers," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings, Inc. "With the clinical trial confirming our longstanding belief around the safety and efficacy of CaverStem(R), we are increasing personnel and marketing in order to accelerate adoption."
"I am excited to be the first CaverStem(R) provider in Hawaii and help all those men that have suffered in silence for years," added Dr. Scott Sanderson, MD at Elite Health Hawaii. "CaverStem(R) is the only solution that addresses the root cause of erectile dysfunction by regenerating cells in the penile region leading to increased erectile firmness, erection duration and sometimes even size."
To learn more about CaverStem(R), please visit www.CaverStem.com
About Erectile Dysfunction
Erectile dysfunction (ED) is characterized by the lack of ability to achieve and maintain penile erection for intercourse. Methods used to quantify ED include the Erectile Function Visual Analog Scale (EF-VAS) and the International Index of Erectile Function (IIEF-5), however clinically it is primarily diagnosed based on symptomology. In our aging society, ED is becoming an increasing problem. According to one study 39% of men at age 40 experience symptoms of ED, whereas by age 70 the incidence rises to 67%. In this latter age group, it is believed that 50-85% of ED cases are associated with hypertension, diabetes, cardiovascular disease and dyslipidemia. Overall, it is estimated that 10-30 million Americans suffer from this condition.
About Edge Media Network
The Gay & Lesbian advertising market encapsulates 35 million Americans with a combined spending power of over $500 billion [Simmons Market Research Bureau]. Gay Americans are 1.5 times more likely to have a high-speed connection to the internet in their homes and businesses [Witeck-Combs/Harris Interactive] and 78% of them prefer to buy from companies who advertise directly to them [Greenfield Online].
EDGE publishes the world's only network for Lesbian, Gay, Bisexual and Transgender (LGBT) news & entertainment. Our publishing platforms support fast-growing readerships in major metropolitan areas across the United States; and our industry-leading mobile product line is the world's go-to source for LGBT news. In 2014, our high-quality journalism reached over 5 million unique readers via these best-of-breed platforms.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of urology, neurology and orthopedics and trades on the OTC under the ticker symbol CELZ. For more information, please visit www.CreativeMedicalTechnology.com.
Forward Looking Statements
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.
View original content to download multimedia:http://www.prnewswire.com/news-releases/creative-medical-technology-holdings-partners-with-edge-media-network-to-accelerate-caverstem-adoption-300915786.html
SOURCE Creative Medical Technology Holdings, Inc.
/CONTACT: Timothy Warbington, CEO, 480.789.9939
/Web site: http://creativemedicaltechnology.com
> Dow Jones Newswires
September 11, 2019 07:45 ET (11:45 GMT)
ALKM Yes but a few less now with a larger Bid
Alkame Holdings, Inc.
OTC BBN : ALKM
$0.0005 0.00 (25.00%)
Bid/Ask
0.0004 / 0.0005
B/A Size
47,885,300 X 13,782,400
Volume
3,004,200
ALKM Nice bid and NO Sellers Down Here
Alkame Holdings, Inc.
OTC BBN : ALKM
$0.0005 0.00 (25.00%)
Bid/Ask
0.0004 / 0.0005
B/A Size
42,885,300 X 15,782,400
Volume
1,004,200
Bell Food & Beverage, Inc.
This Website Is A Work In Process & Under Construction
http://bellcampus.com/company-store/?fbclid=IwAR0xg6p7Esw82CDd3ErHODAFiAHI65d5HRksYGToWBCn7d51vKWD_hs4moM
Update: Creative Medical Technology Holdings Inc.
·
?As noted in our PR this week, our CaverStem® clinical trial information has been updated to reflect the addition of the 100 patient clinical registry.?
?https://clinicaltrials.gov/ct2/show/NCT03699943?
Creative Medical Technology Holdings Inc.
·
CELZ Board of Directors Member, Dr. Amit Patel, discussing the significance of the completion of the CaverStem® clinical trial report when looking at the progression from initial research in 2013 through its' first phase of commercialization.
https://www.facebook.com/CreativeMedicalTechnologyHoldings/photos/a.234891657035014/625205388003637/?type=3&theater
Clinical Trials Updated Today.
CELZ Recruitment Status : Completed
First Posted : October 9, 2018
Last Update Posted : September 6, 2019
https://clinicaltrials.gov/ct2/show/record/NCT03699943
CELZ Active Comparator: Caverstem 2.0 - Clinical Registry
Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. 20 cc
Intervention: Procedure: CaverStem
CELZ Recruitment Status : Completed
First Posted : October 9, 2018
Last Update Posted : September 6, 2019
https://clinicaltrials.gov/ct2/show/record/NCT03699943
ALKM now is too late to fold your hand #88
NEW Auditor and financials should be forthcoming
You've got to know when to hold 'em
Know when to fold 'em
Know when to walk away
And know when to run
You never count your money
When you're sittin' at the table
There'll be time enough for countin'
When the dealin's done
Every gambler knows
That the secret to survivin'
Is knowin' what to throw away
And knowin' what to keep
'Cause every hand's a winner
And every hand's a loser
ARYC PS If you haven't seen the video yet watch it^^
https://ih.advfn.com/videos/educational/arrayit-fingerstick-allergy-program-overview_rMetb4IPYnA
ARYC Thanks for that Pic. A Nice one.
CELZ flippers out of shares BLUE Skies ahead
Creative Medical Technology Holdings Reports completion and submission of Clinical Trial Data on CaverStem(R) Procedure for Drug Resistant Erectile Dysfunction Patients
8:15 AM ET 9/4/19 | Dow Jones
Patients Who Underwent Patented Penile Regenerative Procedure Using Their Own Bone Marrow Concentrate will be Described in Peer Reviewed Paper
PHOENIX, Sept. 4, 2019 /PRNewswire/ -- Creative Medical Technology Holdings (OTC-CELZ) reported today completion of data analysis and submission of a research paper describing a total of 140 patients treated with the CaverStem(R) procedure. The patients suffered from erectile dysfunction for whom standard drug interventions such as Cialis, Levitra, and Viagra (PDE-5) were ineffective.
The data analysis demonstrated that primary end-point of the study was met.
"It is very exciting to see the patented cell based intervention that we first described in peer reviewed literature in our 2013 publication(1) has now grown to become a commercialized procedure, available through qualified physicians, after completing a clinical trial with independent monitoring and oversight for safety and efficacy," said Amit Patel, MD, MS, Board Member of the Company.
In the submitted paper, a total of 40 patients were treated in the primary trial and 100 in the clinical registry. This signifies one of the largest clinical studies of a non-drug treatment for erectile dysfunction.
"The current data is derived from cells that are extracted from the same patient that they are to be used on, and that the cells are not chemically or biologically manipulated. The devices used for extraction and concentration of the cells are FDA cleared. This approach is completely different from unethical and potentially dangerous approaches other groups are using including non-matched stem cells or fat derived stem cells using 'home-made' isolation protocols."
"Since founding the company and acquisition of the technology, through patent prosecution to engaging in the clinical trials and now in the treatment of patients in multiple locations, we have maintained an ongoing positive outlook for our CaverStem(R) technology. The results which will be published in a peer-reviewed journal as well as reflected on clinicaltrials.gov substantiate our long term belief in the potential safety and efficacy of our technology," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings, Inc. "We are glad to be offering this breakthrough treatment to patients with erectile dysfunction who currently have no other options as part of the ongoing clinical registry."
To learn more, please visit www.caverstem.com
About Erectile Dysfunction
Erectile dysfunction (ED) is characterized by the lack of ability to achieve and maintain penile erection for intercourse. Methods used to quantify ED include the Erectile Function Visual Analog Scale (EF-VAS) and the International Index of Erectile Function (IIEF-5), however clinically it is primarily diagnosed based on symptomology. In our aging society, ED is becoming an increasing problem. According to one study 39% of men at age 40 experience symptoms of ED, whereas by age 70 the incidence rises to 67%. In this latter age group, it is believed that 50-85% of ED cases are associated with hypertension, diabetes, cardiovascular disease and dyslipidemia. Overall, it is estimated that 10-30 million Americans suffer from this condition.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of urology, neurology and orthopedics and trades on the OTC under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com.
Forward Looking Statements
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.
(1) Ichim et al. Intracavernous administration of bone marrow mononuclear cells: a new method of treating erectile dysfunction? J Transl Med. 2013; 11: 139. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718667/
View original content to download multimedia:http://www.prnewswire.com/news-releases/creative-medical-technology-holdings-reports-completion-and-submission-of-clinical-trial-data-on-caverstem-procedure-for-drug-resistant-erectile-dysfunction-patients-300911480.html
SOURCE Creative Medical Technology Holdings, Inc.
/CONTACT: Timothy Warbington, CEO, 480-789-9939, ceo@creativemedicalhealth.com
/Web site: http://creativemedicaltechnology.com
> Dow Jones Newswires
September 04, 2019 08:15 ET (12:15 GMT)
Creative Medical Technology Holdings Inc.
4 hrs ·
We are pleased to announce the completion of the data analysis and submission of a research paper describing a total of 140 patients treated with the CaverStem® procedure.
In the submitted paper, a total of 40 patients were treated in the primary trial and 100 in the clinical registry. This signifies one of the largest clinical studies of a non-drug treatment for erectile dysfunction.
https://www.prnewswire.com/…/creative-medical-technology-ho…
CELZ The 8-K should be out after hrs or in the morning to continue the RUN Good Luck
CELZ 2 new Videos from 1 day ago.
CELZ 60+ mil traded 1st hr.
CELZ NEWS 9/4/19 Creative Medical Technology Holdings Reports completion and submission of Clinical Trial Data on CaverStem(R) Procedure for Drug Resistant Erectile Dysfunction Patients
8:15 AM ET 9/4/19 | Dow Jones
Patients Who Underwent Patented Penile Regenerative Procedure Using Their Own Bone Marrow Concentrate will be Described in Peer Reviewed Paper
PHOENIX, Sept. 4, 2019 /PRNewswire/ -- Creative Medical Technology Holdings (OTC-CELZ) reported today completion of data analysis and submission of a research paper describing a total of 140 patients treated with the CaverStem(R) procedure. The patients suffered from erectile dysfunction for whom standard drug interventions such as Cialis, Levitra, and Viagra (PDE-5) were ineffective.
The data analysis demonstrated that primary end-point of the study was met.
"It is very exciting to see the patented cell based intervention that we first described in peer reviewed literature in our 2013 publication(1) has now grown to become a commercialized procedure, available through qualified physicians, after completing a clinical trial with independent monitoring and oversight for safety and efficacy," said Amit Patel, MD, MS, Board Member of the Company.
In the submitted paper, a total of 40 patients were treated in the primary trial and 100 in the clinical registry. This signifies one of the largest clinical studies of a non-drug treatment for erectile dysfunction.
"The current data is derived from cells that are extracted from the same patient that they are to be used on, and that the cells are not chemically or biologically manipulated. The devices used for extraction and concentration of the cells are FDA cleared. This approach is completely different from unethical and potentially dangerous approaches other groups are using including non-matched stem cells or fat derived stem cells using 'home-made' isolation protocols."
"Since founding the company and acquisition of the technology, through patent prosecution to engaging in the clinical trials and now in the treatment of patients in multiple locations, we have maintained an ongoing positive outlook for our CaverStem(R) technology. The results which will be published in a peer-reviewed journal as well as reflected on clinicaltrials.gov substantiate our long term belief in the potential safety and efficacy of our technology," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings, Inc. "We are glad to be offering this breakthrough treatment to patients with erectile dysfunction who currently have no other options as part of the ongoing clinical registry."
To learn more, please visit www.caverstem.com
About Erectile Dysfunction
Erectile dysfunction (ED) is characterized by the lack of ability to achieve and maintain penile erection for intercourse. Methods used to quantify ED include the Erectile Function Visual Analog Scale (EF-VAS) and the International Index of Erectile Function (IIEF-5), however clinically it is primarily diagnosed based on symptomology. In our aging society, ED is becoming an increasing problem. According to one study 39% of men at age 40 experience symptoms of ED, whereas by age 70 the incidence rises to 67%. In this latter age group, it is believed that 50-85% of ED cases are associated with hypertension, diabetes, cardiovascular disease and dyslipidemia. Overall, it is estimated that 10-30 million Americans suffer from this condition.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of urology, neurology and orthopedics and trades on the OTC under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com.
Forward Looking Statements
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.
(1) Ichim et al. Intracavernous administration of bone marrow mononuclear cells: a new method of treating erectile dysfunction? J Transl Med. 2013; 11: 139. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718667/
View original content to download multimedia:http://www.prnewswire.com/news-releases/creative-medical-technology-holdings-reports-completion-and-submission-of-clinical-trial-data-on-caverstem-procedure-for-drug-resistant-erectile-dysfunction-patients-300911480.html
SOURCE Creative Medical Technology Holdings, Inc.
/CONTACT: Timothy Warbington, CEO, 480-789-9939, ceo@creativemedicalhealth.com
/Web site: http://creativemedicaltechnology.com
> Dow Jones Newswires
September 04, 2019 08:15 ET (12:15 GMT)
CELZ 2 important dates to the publishment of the Trials
Adverse events [ Time Frame: Baseline 12 months ]
Actual Primary Completion Date August 31, 2018 (Final data collection date for primary outcome measure)
Make one owens decisions :)
https://clinicaltrials.gov/ct2/show/record/NCT03699943
CELZ at least is isn't a R/S and none in the near future.
Have a great Long Weekend ALKMers. FL people stay safe.
ARYC The only thing Taub will get is discount Disney tickets for this weekend.
VIBI Bring on the News and SHOOT out of the tripps
SIPC summer almost over
Sept 2nd is Labor Day, no trading.
ARYC 5 green days and one small (less than 10%) red isn't Bad.
Load the Boat before Fall season starts.
U.S. securities exchanges are closed September 2 for Labor Day
ALKM load up before fall starts.
U.S. securities exchanges are closed September 2 for Labor Day
GRDO Ya ws wondering why hanging around
Who cares as long is it is before 11:59pm it will still be monday it is not like U can do anything with it till Tues 9:30am
GRDO I want it to succeed.